Translational Development Acquisition (TDACW) Net Income towards Common Stockholders (2024 - 2026)

Translational Development Acquisition (TDACW) has reported Net Income towards Common Stockholders for 3 consecutive years, with $741913.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Income towards Common Stockholders fell 41.96% year-over-year to $741913.0; the trailing twelve-month figure through Jun 2026 stood at $4.4 million (up 82.83% YoY), and the FY2025 full-year result was $5.0 million, up 7729.42% from the prior year.
• Net Income towards Common Stockholders slipped to $741913.0 in Q2 2026 per TDACW's latest filing, from $1.0 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $1.3 million in Q3 2025 and bottomed at -$61283.0 in Q3 2024.
• Historically, Net Income towards Common Stockholders has averaged $842145.6 across 3 years, with a median of $1.1 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders surged 46709.98% in 2025, then slumped 41.96% in 2026.
• Over 3 years, Net Income towards Common Stockholders stood at -$2696.0 in 2024, then soared by 46709.98% to $1.3 million in 2025, then plunged by 40.96% to $741913.0 in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $741913.0, $1.0 million, and $1.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.